ClinicalTrials.Veeva

Menu

Hypertension Treatment in Nigeria 2.0 (HTN 2)

The Washington University logo

The Washington University

Status

Not yet enrolling

Conditions

Hypertension (HTN)

Treatments

Other: Implementation of a modified WHO HEARTS Hypertension Treatment Bundle

Study type

Interventional

Funder types

Other
NIH

Identifiers

NCT07351162
R01HL144708 (U.S. NIH Grant/Contract)
UATH/HREC/PR/557/A2

Details and patient eligibility

About

The purpose of the second phase of the Hypertension Treatment in Nigeria (HTN 2.0) Program is to build upon the success of the first phase of the HTN Program (2020-2023), which implemented the WHO HEARTS package across 60 primary healthcare centers (PHCs) in the Federal Capital Territory, Nigeria. This program demonstrated significant improvements in hypertension treatment and control. HTN 2.0 will expand implementation of the HEARTS bundle to 5 new states in 5 geopolitical zones in Nigeria (Abia, Delta, Gombe, Jigawa, and Oyo) while also evaluating sustainment of hypertension control in the Federal Capital Territory.

Enrollment

10,000 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adults (≥18 years old),
  • Elevated blood pressure (SBP ≥ 140 mmHg or DBP ≥ 90 mmHg) documented or measured by a health care professional (e.g., physician, community health extension worker, or community health officer) on two separate occasions or taking a BP-lowering medication, or a history of hypertension.
  • Pregnant women are eligible for this program, or
  • Cognitively impaired adults are eligible for this program..

Exclusion criteria

This program will not include any of the following special populations:

  • Individuals who are not yet adults (minors): i.e. infants, children, or teenagers <18 years old, or
  • Prisoners or other detained individuals.

Trial design

Primary purpose

Health Services Research

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

10,000 participants in 1 patient group

Primary Health Care Centers
Experimental group
Description:
50 primary healthcare centers across five Nigerian states will be selected to implement a hypertension treatment program based on the WHO HEARTS hypertension technical package.
Treatment:
Other: Implementation of a modified WHO HEARTS Hypertension Treatment Bundle

Trial documents
1

Trial contacts and locations

0

Loading...

Central trial contact

Mark Huffman, MD; Dike Ojji, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems